



Massimo Terzolo, MD

Massimo Terzolo is Full Professor of Internal Medicine at the University of Turin. He is Director of the Department of Clinical and Biological Sciences, and Head of the Division of Internal Medicine at University Hospital San Luigi Gonzaga in Orbassano.

He is a clinical and translational researcher in adrenal and pituitary diseases, with an important clinical expertise in the management of patients with adrenal tumors.

His research enabled significant advances in diagnosing and treating patients with adrenal incidentaloma and patients with adrenocortical carcinoma.

He contributed to the Guidelines of the European Society of Endocrinology and the European Network for the Study of Adrenal Tumors (ENSAT) on Adrenal Incidentalomas (2016) and co-chaired the guideline on Adrenocortical Carcinoma (2018) and contributed to the ESMO (European Society of Medical Oncology) guidelines on adrenocortical carcinoma and malignant pheochromocytoma (2020).

He authored more than 270 papers on peer-reviewed journals. H-index: 62.

SELECTED PUBLICATIONS

1. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. **Terzolo M**, et al. *Lancet Diabetes Endocrinol*. 2023 Aug 21:S2213-8587(23)00193-6
2. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Deutschbein T, ... **Terzolo M**§, Fassnacht M§. §Joint senior author *Lancet Diabetes Endocrinol*. 2022 Jul;10(7):499-508.
3. Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study. Reimondo G, Castellano E, Grosso M, Priotto R, Puglisi S, Pia A, Pellegrino M, Borretta G, **Terzolo M**. *J Clin Endocrinol Metab*. 2020 Apr 1;105(4):dgz284.
4. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. Calabrese A, Basile V, Puglisi S, Perotti P, Pia A, Saba L, Berchiolla P, Porpiglia F, Veltri A, Volante M, Reimondo G, Berruti A, **Terzolo M**. *Eur J Endocrinol*. 2019 Jun 1;180(6):387-396
5. Adjuvant mitotane treatment for adrenocortical carcinoma. **Terzolo M**, et al. *New England Journal of Medicine*, 2007 Jun. 356:2372-2380.